Amneal Pharmaceuticals Inc. (NYSE:AMRX) previous close was $5.65 while the outstanding shares total 148.01M. The firm has a beta of 1.26. AMRX’s shares traded lower over the last trading session, losing -1.06% on 05/27/21. The shares fell to a low of $5.58 before closing at $5.59. Intraday shares traded counted 0.52 million, which was 71.57% higher than its 30-day average trading volume of 1.83M. The stock’s Relative Strength Index (RSI) is 46.61, with weekly volatility at 2.64% and ATR at 0.21. The AMRX stock’s 52-week price range has touched low of $3.45 and a $7.45 high.
Investors have identified the Drug Manufacturers – Specialty & Generic company Amneal Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.68 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Amneal Pharmaceuticals Inc. (AMRX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For AMRX, the company has in raw cash 455.81 million on their books with 29.82 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 1.56 billion total, with 636.78 million as their total liabilities.
AMRX were able to record 135.44 million as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by 108.69 million. In cash movements, the company had a total of 148.13 million as operating cash flow.
Potential earnings growth for Amneal Pharmaceuticals Inc. (AMRX)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/12/2021 quarter of the year, Amneal Pharmaceuticals Inc. recorded a total of 493.11 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -1.1% coming in sequential stages and their sales for the 08/12/2021 quarter reducing by -3.43%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 301.54 million trying to sell their products during the last quarter, with the result yielding a gross income of 191.56 million. This allows shareholders to hold on to 148.01M with the recently reported earning now reading 0.10 cents per share. This is a figure that compared to analyst’s prediction for their 08/12/2021 (0.19 cents a share).
Having a look at the company’s valuation, the company is expected to record 0.86 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on AMRX sounds very interesting.
Is the stock of AMRX attractive?
In related news, Executive Vice President, Todisco Joseph sold 36,330 shares of the company’s stock in a transaction that recorded on Mar 15. The sale was performed at an average price of 6.82, for a total value of 247,865. As the sale deal closes, the Executive Vice President, Shah Nikita now sold 36,330 shares of the company’s stock, valued at 249,489. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.20%.
5 out of 11 analysts covering the stock have rated it a Buy, while 5 have maintained a Hold recommendation on Amneal Pharmaceuticals Inc.. 1 analysts has assigned a Sell rating on the AMRX stock. The 12-month mean consensus price target for the company’s shares has been set at $6.45.